{
    "info": {
        "nct_id": "NCT02860000",
        "official_title": "Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer",
        "inclusion_criteria": "* PRE-REGISTRATION ELIGIBILITY\n* Post-menopausal defined as\n\n  * Age >= 60 and amenorrhea > 12 consecutive months, OR\n  * Age < 60 and amenorrhea > 12 consecutive months without another cause and documented follicle stimulating hormone (FSH) level of > 35 mIU/mL, OR\n  * Previous bilateral oophorectomy\n* Histologic proof of metastatic or locally advanced, unresectable breast cancer\n* History of ER positive (+) (>= 10% of cells positive on hematoxylin and eosin stain [H&E]), HER2 negative (-) breast cancer disease, either as a\n\n  * History of primary, operable ER+/HER2- invasive breast cancer OR\n  * History of de novo metastatic breast cancer that is ER+/HER2-\n\n    * Note: HER2- (negative) disease defined as one of the following:\n\n      * HER2 immunohistochemistry (IHC) expression of 0, 1+ and in-situ hybridization (ISH) non-amplified\n      * HER2 IHC expression of 0, 1+ and ISH not done\n      * HER2 IHC expression of 2+ and ISH non-amplified\n      * IHC not done and ISH non-amplified\n* Prior treatment\n\n  * No more than two prior chemotherapy regimens in the metastatic setting\n  * Prior treatment with fulvestrant in the metastatic setting is required, except for patients with a history of ER-negative metastatic breast cancer\n  * Unlimited prior endocrine therapy regimens in the metastatic setting are allowed\n  * No prior treatment with an aurora Kinase inhibitor (either an aurora A or pan-aurora kinase inhibitor)\n* Disease that is measurable where:\n\n  * A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)\n  * A malignant lymph node is considered measurable if its short axis is >= 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm); Note: tumor lesions in a previously irradiated area are not considered measurable disease; Note: disease that is measurable by physical examination only is not eligible\n* No history of tumors involving spinal cord or heart\n* History of brain metastases as per the following criteria:\n\n  * Patients with a history of resected brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including < 28 days prior to pre-registration\n  * Patients who receive stereotactic radiosurgery or whole brain radiation for brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including < 28 days prior to pre-registration\n* Fully recovered from acute, reversible effects of prior therapy regardless of interval since last treatment;\n\n  * EXCEPTION: neuropathies - if grade 2 neuropathies have been stable for at least 3 months since completion of prior treatment patient is eligible\n* Eastern Cooperative Oncology Group (ECOG) performance status: 0, 1, 2\n* Not receiving administration of proton pump inhibitor, H2 antagonist, or pancreatic enzymes\n* Willing to limit daily alcohol intake to the following: one 12-oz glass of beer, one 6-oz glass of wine, or one 1.5-oz portion of 80-proof alcohol\n* No uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Uncontrolled symptomatic cardiac arrhythmia\n  * Uncontrolled hypertension (defined as blood pressure > 160/90)\n* No history of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease; requirement for supplemental oxygen\n* No other active second malignancy other than non-melanoma skin cancers and in situ cervical cancers within 5 years of registration\n\n  * NOTE: A second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for at least 5 years prior to registration\n* Ability to provide written informed consent\n* Willing to return to enrolling institution for follow-up during the active treatment; event monitoring following completion of therapy may occur outside the enrolling institution\n* No history of myocardial infarction =< 6 months prior to pre-registration or New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities\n* No prior allogeneic bone marrow or organ transplantation\n* No known clinical finding or suspicion of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C\n* No co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Able to swallow oral medication\n* No known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease\n* No visceral crisis: Visceral crisis is not the mere presence of visceral metastases, but implies severe organ dysfunction as assessed by symptoms and signs, laboratory studies, and rapid progression of disease\n* No requirement for constant administration of proton pump inhibitor, H2 antagonist, or pancreatic enzymes\n* Willing to undergo a biopsy of a metastatic site of breast disease for central laboratory determination of ER and correlative research purposes\n* REGISTRATION ELIGIBILITY CRITERIA\n* =< 28 days post pre-registration\n* Central ER determination on pre-registration biopsy completed\n* Absolute neutrophil count (ANC) >= 1500/mm^3\n* Platelet count >= 100,000/mm^3\n* Hemoglobin >= 9.0 g/dL\n* Total bilirubin =< 1.5 x upper limit of normal (ULN)\n* Alanine transaminase (ALT) =< 3 x ULN (=< 5 x ULN for patients with liver involvement)\n* Calculated creatinine clearance must be >= 45 ml/min using the Cockcroft-Gault formula\n* Willing to provide blood and tissue for correlative research purposes\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* REGISTRATION EXCLUSION CRITERIA\n* Any of the following therapies prior to registration:\n\n  * Chemotherapy =< 21 days\n  * Immunotherapy =< 21 days\n  * Biologic therapy =< 21 days\n  * Hormonal therapy =< 14 days\n  * Monoclonal antibodies =< 14 days\n  * Radiation therapy =< 14 days\n* Administration of myeloid growth factors or platelet transfusion =< 14 days prior to registration\n* Systemic infection requiring intravenous (IV) antibiotic therapy =< 14 days prior to registration\n* Treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort =< 14 days prior to registration\n* Receipt of corticosteroids =< 7 days prior to registration, unless patient has been taking a continuous dose of no more than 15 mg/day of prednisone for at least 30 days prior to registration",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* No prior allogeneic bone marrow or organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "No prior allogeneic bone marrow ... transplantation",
                    "criterion": "allogeneic bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No prior ... organ transplantation",
                    "criterion": "organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment",
                    "criterion": "prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fully recovered from acute, reversible effects of prior therapy regardless of interval since last treatment;",
            "criterions": [
                {
                    "exact_snippets": "Fully recovered from acute, reversible effects of prior therapy",
                    "criterion": "recovery from acute, reversible effects of prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "fully recovered"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease that is measurable where:",
            "criterions": [
                {
                    "exact_snippets": "Disease that is measurable",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* =< 28 days post pre-registration",
            "criterions": [
                {
                    "exact_snippets": "=< 28 days post pre-registration",
                    "criterion": "time since pre-registration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A malignant lymph node is considered measurable if its short axis is >= 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm); Note: tumor lesions in a previously irradiated area are not considered measurable disease; Note: disease that is measurable by physical examination only is not eligible",
            "criterions": [
                {
                    "exact_snippets": "A malignant lymph node is considered measurable if its short axis is >= 1.5 cm when assessed by CT scan",
                    "criterion": "malignant lymph node short axis (by CT scan)",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "CT scan"
                        }
                    ]
                },
                {
                    "exact_snippets": "CT scan slice thickness recommended to be no greater than 5 mm",
                    "criterion": "CT scan slice thickness",
                    "requirements": [
                        {
                            "requirement_type": "thickness",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "mm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor lesions in a previously irradiated area are not considered measurable disease",
                    "criterion": "tumor lesions in previously irradiated area",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "disease that is measurable by physical examination only is not eligible",
                    "criterion": "disease measurable by physical examination only",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of brain metastases as per the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "History of brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to swallow oral medication",
            "criterions": [
                {
                    "exact_snippets": "Able to swallow oral medication",
                    "criterion": "ability to swallow oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to provide blood and tissue for correlative research purposes",
            "criterions": [
                {
                    "exact_snippets": "Willing to provide blood ... for correlative research purposes",
                    "criterion": "blood sample provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willing to provide ... tissue for correlative research purposes",
                    "criterion": "tissue sample provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Central ER determination on pre-registration biopsy completed",
            "criterions": [
                {
                    "exact_snippets": "Central ER determination on pre-registration biopsy completed",
                    "criterion": "central ER determination on pre-registration biopsy",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous bilateral oophorectomy",
            "criterions": [
                {
                    "exact_snippets": "Previous bilateral oophorectomy",
                    "criterion": "bilateral oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled symptomatic cardiac arrhythmia",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled symptomatic cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic congestive heart failure",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 100,000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologic proof of metastatic or locally advanced, unresectable breast cancer",
            "criterions": [
                {
                    "exact_snippets": "Histologic proof of metastatic or locally advanced, unresectable breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "histologic proof",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "metastatic",
                                "locally advanced, unresectable"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No history of tumors involving spinal cord or heart",
            "criterions": [
                {
                    "exact_snippets": "No history of tumors involving spinal cord",
                    "criterion": "history of tumors involving spinal cord",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No history of tumors involving...heart",
                    "criterion": "history of tumors involving heart",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension (defined as blood pressure > 160/90)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension (defined as blood pressure > 160/90)",
                    "criterion": "blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "systolic blood pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 160,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "diastolic blood pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "mmHg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* EXCEPTION: neuropathies - if grade 2 neuropathies have been stable for at least 3 months since completion of prior treatment patient is eligible",
            "criterions": [
                {
                    "exact_snippets": "neuropathies - if grade 2 neuropathies have been stable for at least 3 months since completion of prior treatment",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "2"
                        },
                        {
                            "requirement_type": "stability_duration_since_prior_treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HER2 immunohistochemistry (IHC) expression of 0, 1+ and in-situ hybridization (ISH) non-amplified",
            "criterions": [
                {
                    "exact_snippets": "HER2 immunohistochemistry (IHC) expression of 0, 1+",
                    "criterion": "HER2 immunohistochemistry (IHC) expression",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1+"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "in-situ hybridization (ISH) non-amplified",
                    "criterion": "HER2 in-situ hybridization (ISH) status",
                    "requirements": [
                        {
                            "requirement_type": "amplification status",
                            "expected_value": "non-amplified"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: A second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for at least 5 years prior to registration",
            "criterions": [
                {
                    "exact_snippets": "A second malignancy is not considered active if all treatment for that malignancy is completed",
                    "criterion": "second malignancy",
                    "requirements": [
                        {
                            "requirement_type": "treatment completion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the patient has been disease-free for at least 5 years prior to registration",
                    "criterion": "second malignancy",
                    "requirements": [
                        {
                            "requirement_type": "disease-free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of ER positive (+) (>= 10% of cells positive on hematoxylin and eosin stain [H&E]), HER2 negative (-) breast cancer disease, either as a",
            "criterions": [
                {
                    "exact_snippets": "History of ER positive (+) (>= 10% of cells positive on hematoxylin and eosin stain [H&E])",
                    "criterion": "estrogen receptor (ER) status",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "percentage of cells positive",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "detection method",
                            "expected_value": "hematoxylin and eosin stain (H&E)"
                        }
                    ]
                },
                {
                    "exact_snippets": "HER2 negative (-) breast cancer disease",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "negativity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age < 60 and amenorrhea > 12 consecutive months without another cause and documented follicle stimulating hormone (FSH) level of > 35 mIU/mL, OR",
            "criterions": [
                {
                    "exact_snippets": "Age < 60",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 60,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "amenorrhea > 12 consecutive months without another cause",
                    "criterion": "amenorrhea",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "without another cause"
                        }
                    ]
                },
                {
                    "exact_snippets": "documented follicle stimulating hormone (FSH) level of > 35 mIU/mL",
                    "criterion": "follicle stimulating hormone (FSH) level",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 35,
                                "unit": "mIU/mL"
                            }
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who receive stereotactic radiosurgery or whole brain radiation for brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including < 28 days prior to pre-registration",
            "criterions": [
                {
                    "exact_snippets": "Patients who receive stereotactic radiosurgery or whole brain radiation for brain metastases",
                    "criterion": "history of stereotactic radiosurgery or whole brain radiation for brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "are eligible only if they are asymptomatic",
                    "criterion": "symptoms from brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have stable MRI scans for 3 consecutive months, including < 28 days prior to pre-registration",
                    "criterion": "MRI scan stability of brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "most recent MRI timing",
                            "expected_value": {
                                "operator": "<",
                                "value": 28,
                                "unit": "days prior to pre-registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No known clinical finding or suspicion of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C",
            "criterions": [
                {
                    "exact_snippets": "No known clinical finding or suspicion of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence or suspicion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No known clinical finding or suspicion of ... hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence or suspicion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No known clinical finding or suspicion of ... hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence or suspicion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HER2 IHC expression of 2+ and ISH non-amplified",
            "criterions": [
                {
                    "exact_snippets": "HER2 IHC expression of 2+",
                    "criterion": "HER2 IHC expression",
                    "requirements": [
                        {
                            "requirement_type": "expression level",
                            "expected_value": "2+"
                        }
                    ]
                },
                {
                    "exact_snippets": "ISH non-amplified",
                    "criterion": "HER2 ISH status",
                    "requirements": [
                        {
                            "requirement_type": "amplification status",
                            "expected_value": "non-amplified"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of de novo metastatic breast cancer that is ER+/HER2-",
            "criterions": [
                {
                    "exact_snippets": "History of de novo metastatic breast cancer",
                    "criterion": "de novo metastatic breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ER+/HER2-",
                    "criterion": "breast cancer receptor status",
                    "requirements": [
                        {
                            "requirement_type": "estrogen receptor status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >= 60 and amenorrhea > 12 consecutive months, OR",
            "criterions": [
                {
                    "exact_snippets": "Age >= 60",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "amenorrhea > 12 consecutive months",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No other active second malignancy other than non-melanoma skin cancers and in situ cervical cancers within 5 years of registration",
            "criterions": [
                {
                    "exact_snippets": "No other active second malignancy",
                    "criterion": "active second malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "other than non-melanoma skin cancers and in situ cervical cancers",
                    "criterion": "type of second malignancy",
                    "requirements": [
                        {
                            "requirement_type": "allowed types",
                            "expected_value": [
                                "non-melanoma skin cancers",
                                "in situ cervical cancers"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "within 5 years of registration",
                    "criterion": "time since diagnosis of second malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Not receiving administration of proton pump inhibitor, H2 antagonist, or pancreatic enzymes",
            "criterions": [
                {
                    "exact_snippets": "Not receiving administration of proton pump inhibitor",
                    "criterion": "proton pump inhibitor administration",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Not receiving administration of ... H2 antagonist",
                    "criterion": "H2 antagonist administration",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Not receiving administration of ... pancreatic enzymes",
                    "criterion": "pancreatic enzyme administration",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine transaminase (ALT) =< 3 x ULN (=< 5 x ULN for patients with liver involvement)",
            "criterions": [
                {
                    "exact_snippets": "Alanine transaminase (ALT) =< 3 x ULN (=< 5 x ULN for patients with liver involvement)",
                    "criterion": "alanine transaminase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (for patients with liver involvement)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status: 0, 1, 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status: 0, 1, 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of primary, operable ER+/HER2- invasive breast cancer OR",
            "criterions": [
                {
                    "exact_snippets": "History of primary, operable ER+/HER2- invasive breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "primary",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "operable",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ER status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "invasive",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of resected brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including < 28 days prior to pre-registration",
            "criterions": [
                {
                    "exact_snippets": "history of resected brain metastases",
                    "criterion": "history of resected brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "are eligible only if they are asymptomatic",
                    "criterion": "symptoms of brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "stable MRI scans for 3 consecutive months, including < 28 days prior to pre-registration",
                    "criterion": "MRI scan stability",
                    "requirements": [
                        {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "most recent MRI timing",
                            "expected_value": {
                                "operator": "<",
                                "value": 28,
                                "unit": "days prior to pre-registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No history of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease; requirement for supplemental oxygen",
            "criterions": [
                {
                    "exact_snippets": "No history of uncontrolled sleep apnea syndrome",
                    "criterion": "sleep apnea syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history of uncontrolled disease",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease",
                    "criterion": "conditions resulting in excessive daytime sleepiness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "requirement for supplemental oxygen",
                    "criterion": "requirement for supplemental oxygen",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HER2 IHC expression of 0, 1+ and ISH not done",
            "criterions": [
                {
                    "exact_snippets": "HER2 IHC expression of 0, 1+",
                    "criterion": "HER2 IHC expression",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1+"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "ISH not done",
                    "criterion": "ISH test",
                    "requirements": [
                        {
                            "requirement_type": "performed",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No requirement for constant administration of proton pump inhibitor, H2 antagonist, or pancreatic enzymes",
            "criterions": [
                {
                    "exact_snippets": "No requirement for constant administration of proton pump inhibitor",
                    "criterion": "requirement for constant administration of proton pump inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No requirement for constant administration of ... H2 antagonist",
                    "criterion": "requirement for constant administration of H2 antagonist",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No requirement for constant administration of ... pancreatic enzymes",
                    "criterion": "requirement for constant administration of pancreatic enzymes",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ongoing or active infection",
            "criterions": [
                {
                    "exact_snippets": "Ongoing or active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to limit daily alcohol intake to the following: one 12-oz glass of beer, one 6-oz glass of wine, or one 1.5-oz portion of 80-proof alcohol",
            "criterions": [
                {
                    "exact_snippets": "Willing to limit daily alcohol intake to the following: one 12-oz glass of beer, one 6-oz glass of wine, or one 1.5-oz portion of 80-proof alcohol",
                    "criterion": "daily alcohol intake",
                    "requirements": [
                        {
                            "requirement_type": "maximum quantity",
                            "expected_value": [
                                ">= 0 and <= 12 oz beer OR >= 0 and <= 6 oz wine OR >= 0 and <= 1.5 oz 80-proof alcohol"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Willing to limit daily alcohol intake",
                    "criterion": "willingness to limit alcohol intake",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unlimited prior endocrine therapy regimens in the metastatic setting are allowed",
            "criterions": [
                {
                    "exact_snippets": "Unlimited prior endocrine therapy regimens in the metastatic setting are allowed",
                    "criterion": "prior endocrine therapy regimens in the metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "maximum number",
                            "expected_value": "unlimited"
                        },
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to provide written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Ability to provide written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability to provide",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION ELIGIBILITY",
            "criterions": [
                {
                    "exact_snippets": "PRE-REGISTRATION ELIGIBILITY",
                    "criterion": "pre-registration eligibility",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* IHC not done and ISH non-amplified",
            "criterions": [
                {
                    "exact_snippets": "IHC not done",
                    "criterion": "IHC (immunohistochemistry) test",
                    "requirements": [
                        {
                            "requirement_type": "performed",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "ISH non-amplified",
                    "criterion": "ISH (in situ hybridization) test result",
                    "requirements": [
                        {
                            "requirement_type": "amplification status",
                            "expected_value": "non-amplified"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with fulvestrant in the metastatic setting is required, except for patients with a history of ER-negative metastatic breast cancer",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with fulvestrant in the metastatic setting is required",
                    "criterion": "prior treatment with fulvestrant in the metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except for patients with a history of ER-negative metastatic breast cancer",
                    "criterion": "history of ER-negative metastatic breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No more than two prior chemotherapy regimens in the metastatic setting",
            "criterions": [
                {
                    "exact_snippets": "No more than two prior chemotherapy regimens in the metastatic setting",
                    "criterion": "number of prior chemotherapy regimens in the metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "regimens"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No uncontrolled intercurrent illness including, but not limited to:",
            "criterions": [
                {
                    "exact_snippets": "No uncontrolled intercurrent illness",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Calculated creatinine clearance must be >= 45 ml/min using the Cockcroft-Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Calculated creatinine clearance must be >= 45 ml/min using the Cockcroft-Gault formula",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to undergo a biopsy of a metastatic site of breast disease for central laboratory determination of ER and correlative research purposes",
            "criterions": [
                {
                    "exact_snippets": "Willing to undergo a biopsy of a metastatic site of breast disease",
                    "criterion": "willingness to undergo biopsy",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "biopsy site",
                            "expected_value": "metastatic site of breast disease"
                        }
                    ]
                },
                {
                    "exact_snippets": "for central laboratory determination of ER",
                    "criterion": "biopsy sample for ER determination",
                    "requirements": [
                        {
                            "requirement_type": "purpose",
                            "expected_value": "central laboratory determination of ER"
                        }
                    ]
                },
                {
                    "exact_snippets": "for ... correlative research purposes",
                    "criterion": "biopsy sample for correlative research",
                    "requirements": [
                        {
                            "requirement_type": "purpose",
                            "expected_value": "correlative research"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unstable angina pectoris",
            "criterions": [
                {
                    "exact_snippets": "Unstable angina pectoris",
                    "criterion": "unstable angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)",
            "criterions": [
                {
                    "exact_snippets": "A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= 2.0 cm with chest x-ray",
                    "criterion": "non-nodal lesion longest diameter (chest x-ray)",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.0,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": "chest x-ray"
                        }
                    ]
                },
                {
                    "exact_snippets": "A non-nodal lesion is considered measurable if its longest diameter can be accurately measured ... as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)",
                    "criterion": "non-nodal lesion longest diameter (CT, PET/CT, or MRI)",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": [
                                "computed tomography (CT) scan",
                                "CT component of a positron emission tomography (PET)/CT",
                                "magnetic resonance imaging (MRI)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Post-menopausal defined as",
            "criterions": [
                {
                    "exact_snippets": "Post-menopausal defined as",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "post-menopausal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease",
            "criterions": [
                {
                    "exact_snippets": "No known gastrointestinal (GI) disease",
                    "criterion": "gastrointestinal (GI) disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No known ... GI procedures that could interfere with the oral absorption or tolerance of alisertib",
                    "criterion": "GI procedures that could interfere with the oral absorption or tolerance of alisertib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "partial gastrectomy",
                    "criterion": "partial gastrectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "history of small intestine surgery",
                    "criterion": "small intestine surgery",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "celiac disease",
                    "criterion": "celiac disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No visceral crisis: Visceral crisis is not the mere presence of visceral metastases, but implies severe organ dysfunction as assessed by symptoms and signs, laboratory studies, and rapid progression of disease",
            "criterions": [
                {
                    "exact_snippets": "No visceral crisis",
                    "criterion": "visceral crisis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "severe organ dysfunction as assessed by symptoms and signs, laboratory studies, and rapid progression of disease",
                    "criterion": "organ dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "rapid progression of disease",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "rate",
                            "expected_value": "rapid"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1500/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1500/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No history of myocardial infarction =< 6 months prior to pre-registration or New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities",
            "criterions": [
                {
                    "exact_snippets": "No history of myocardial infarction =< 6 months prior to pre-registration",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association (NYHA) class III or IV heart failure",
                    "criterion": "heart failure (NYHA class)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA_class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "severe uncontrolled ventricular arrhythmias",
                    "criterion": "ventricular arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "electrocardiographic evidence of acute ischemia",
                    "criterion": "acute ischemia (on ECG)",
                    "requirements": [
                        {
                            "requirement_type": "evidence_on_ECG",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "electrocardiographic evidence of ... active conduction system abnormalities",
                    "criterion": "active conduction system abnormalities (on ECG)",
                    "requirements": [
                        {
                            "requirement_type": "evidence_on_ECG",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to return to enrolling institution for follow-up during the active treatment; event monitoring following completion of therapy may occur outside the enrolling institution",
            "criterions": [
                {
                    "exact_snippets": "Willing to return to enrolling institution for follow-up during the active treatment",
                    "criterion": "willingness to return to enrolling institution for follow-up",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "enrolling institution"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during the active treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No prior treatment with an aurora Kinase inhibitor (either an aurora A or pan-aurora kinase inhibitor)",
            "criterions": [
                {
                    "exact_snippets": "No prior treatment with an aurora Kinase inhibitor (either an aurora A or pan-aurora kinase inhibitor)",
                    "criterion": "prior treatment with an aurora kinase inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
            "criterions": [
                {
                    "exact_snippets": "No co-morbid systemic illnesses",
                    "criterion": "co-morbid systemic illnesses",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "other severe concurrent disease",
                    "criterion": "severe concurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "which, in the judgment of the investigator, would make the patient inappropriate for entry into this study",
                    "criterion": "appropriateness for study entry (per investigator judgment)",
                    "requirements": [
                        {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
                    "criterion": "potential interference with assessment of safety and toxicity",
                    "requirements": [
                        {
                            "requirement_type": "interference",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: HER2- (negative) disease defined as one of the following:",
            "criterions": [
                {
                    "exact_snippets": "HER2- (negative) disease",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort =< 14 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort =< 14 days prior to registration",
                    "criterion": "treatment with clinically significant enzyme inducers",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunotherapy =< 21 days",
            "criterions": [
                {
                    "exact_snippets": "Immunotherapy =< 21 days",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION EXCLUSION CRITERIA",
            "criterions": [
                {
                    "exact_snippets": "REGISTRATION EXCLUSION CRITERIA",
                    "criterion": "registration exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy =< 21 days",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy =< 21 days",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last chemotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic infection requiring intravenous (IV) antibiotic therapy =< 14 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Systemic infection requiring intravenous (IV) antibiotic therapy =< 14 days prior to registration",
                    "criterion": "systemic infection requiring intravenous antibiotic therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last occurrence",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiation therapy =< 14 days",
            "criterions": [
                {
                    "exact_snippets": "Radiation therapy =< 14 days",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hormonal therapy =< 14 days",
            "criterions": [
                {
                    "exact_snippets": "Hormonal therapy =< 14 days",
                    "criterion": "hormonal therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Monoclonal antibodies =< 14 days",
            "criterions": [
                {
                    "exact_snippets": "Monoclonal antibodies =< 14 days",
                    "criterion": "monoclonal antibody administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receipt of corticosteroids =< 7 days prior to registration, unless patient has been taking a continuous dose of no more than 15 mg/day of prednisone for at least 30 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Receipt of corticosteroids =< 7 days prior to registration",
                    "criterion": "corticosteroid receipt",
                    "requirements": [
                        {
                            "requirement_type": "time since last receipt",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "relative to",
                            "expected_value": "prior to registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "unless patient has been taking a continuous dose of no more than 15 mg/day of prednisone for at least 30 days prior to registration",
                    "criterion": "prednisone dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 15,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "continuity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "relative to",
                            "expected_value": "prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Administration of myeloid growth factors or platelet transfusion =< 14 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Administration of myeloid growth factors ... =< 14 days prior to registration",
                    "criterion": "myeloid growth factors administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "platelet transfusion =< 14 days prior to registration",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "time since last transfusion",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Biologic therapy =< 21 days",
            "criterions": [
                {
                    "exact_snippets": "Biologic therapy =< 21 days",
                    "criterion": "biologic therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last biologic therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any of the following therapies prior to registration:",
            "criterions": [
                {
                    "exact_snippets": "Any of the following therapies prior to registration",
                    "criterion": "prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* REGISTRATION ELIGIBILITY CRITERIA",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}